Nuveen LLC Invests $2.01 Million in Nurix Therapeutics, Inc. $NRIX

Nuveen LLC purchased a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 169,145 shares of the company’s stock, valued at approximately $2,009,000. Nuveen LLC owned approximately 0.22% of Nurix Therapeutics at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in shares of Nurix Therapeutics in the fourth quarter valued at about $1,026,000. First Trust Advisors LP bought a new stake in shares of Nurix Therapeutics during the fourth quarter valued at approximately $2,560,000. Dimensional Fund Advisors LP increased its holdings in shares of Nurix Therapeutics by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 506,839 shares of the company’s stock valued at $9,548,000 after purchasing an additional 5,270 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Nurix Therapeutics by 20.7% during the 4th quarter. MetLife Investment Management LLC now owns 42,539 shares of the company’s stock worth $801,000 after buying an additional 7,300 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Nurix Therapeutics by 422.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,885 shares of the company’s stock valued at $280,000 after buying an additional 12,036 shares during the last quarter.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 5,402 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares of the company’s stock, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total transaction of $51,739.08. Following the transaction, the insider owned 69,023 shares of the company’s stock, valued at approximately $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,014 shares of company stock worth $163,014 over the last quarter. 7.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NRIX. Baird R W upgraded Nurix Therapeutics to a “strong-buy” rating in a research report on Tuesday. Oppenheimer restated an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of Nurix Therapeutics in a research report on Thursday, July 31st. Stephens reissued an “overweight” rating and set a $30.00 price target on shares of Nurix Therapeutics in a research note on Thursday, July 10th. UBS Group cut their price objective on shares of Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday, July 10th. Finally, HC Wainwright dropped their target price on shares of Nurix Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.87.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $9.34 on Friday. The company has a market capitalization of $714.04 million, a P/E ratio of -3.58 and a beta of 2.14. The business has a 50-day moving average of $11.20 and a two-hundred day moving average of $11.81. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.27. The firm had revenue of $44.06 million during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. On average, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.